Kt Corporation ADR Aktie
Finanztrends
Deine Einschätzung
Kt Corporation ADR Aktie
Ein signifikanter Verlust für Kt Corporation ADR heute, um -1,27 %.
Was spricht für und gegen Kt Corporation ADR in den nächsten Jahren?
Pro
?
M****
?
A****************
?
W******* i* V********
Kontra
?
U****************
?
L*********** I********** f** d** n******* J****
?
M************
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Kt Corporation ADR im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Kt Corporation ADR | -1,27 % | -2,50 % | -0,64 % | -9,30 % | -1,27 % | 39,29 % | 26,83 % |
| Freenet AG | 1,02 % | -2,55 % | -0,34 % | -16,12 % | -19,59 % | 8,71 % | 14,04 % |
| Philippine Long Distance Telephone Company ADR | -1,18 % | -1,75 % | 4,35 % | -14,72 % | -6,67 % | -19,23 % | -16,00 % |
| Telekom Austria AG | 0,99 % | 0,99 % | 1,80 % | 9,44 % | 13,59 % | 52,01 % | 35,82 % |
Kommentare
News
Kymera Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Kymera Therapeutics, Inc.? Here are five stocks we like better.
- KT-621 atopic dermatitis trial enrollment is complete about six months ahead of schedule, with top-line
Kymera's CEO Sold $6 Million in Stock After a 170% Run
Chief Executive Officer Nello Mainolfi sold 50,000 shares of Kymera Therapeutics (NASDAQ:KYMR) on July 7, 2026, for total proceeds of about $6.0 million, according to an SEC Form 4 filing.
Kymera
Why Kymera Therapeutics Stock Popped This Week
This week was an eventful one for Kymera Therapeutics (NASDAQ: KYMR). The clinical-stage biotech announced the early completion of enrollment in an important clinical trial. It also earned a clutch